由心肌细胞衍生的YOD1通过使STAT3脱和稳定,促进病态心脏缩
Bozhi Ye1,2,3, Wante Lin1, Yucheng Jiang3
1Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Science advances
|June 25, 2025
概括
研究人员发现,二氧化酶YOD1稳定了STAT3,减少了病理性心脏缩. 抑制YOD1或STAT3减轻了心脏重塑,为心脏病提供了新的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 疾病的分子机制.
- 生物化学 生物化学
背景情况:
- 病理性心脏缩仍然是一个重大的临床挑战.
- 识别新的分子点对于开发有效疗法至关重要.
- 在心脏重塑过程中,二维化酶的作用还没有完全被理解.
研究的目的:
- 为了研究二基化酶YOD1在病理性心脏缩中的作用.
- 确定心肌细胞中YOD1的新型相互作用伙伴和下游途径.
- 探索针对YOD1-STAT3轴的治疗潜力.
主要方法:
- 分析YOD1表达在人类和小鼠过度缩的心脏.
- 产生特定于心肌细胞的Yod1淘汰小鼠模型.
- 蛋白质组分析以确定YOD1基质.
- 生物化学测定以确认YOD1-STAT3相互作用和二维化.
- 在体内研究使用血管新素II输注和横向大动脉收缩 (TAC) 模型.
- 药理上抑制YOD1和STAT3.3的作用.
主要成果:
- 在过度缩的心肌中,YOD1表达量中度升高.
- 心肌细胞特异性YOD1淘汰赛减弱了Ang II和TAC诱导的心脏缩.
- 蛋白质组分析确定STAT3是YOD1.1的基质.
- YOD1在STAT3上对K97进行了二氧化,使其稳定,并促进了核转位.
- STAT3 抑制逆转了YOD1 缺乏的抗缩作用.
- 药理上的YOD1抑制减少了Ang II诱导的心室重塑.
结论:
- YOD1在调节病态心脏缩方面发挥着至关重要的作用.
- 在心脏缩中发现了一种新的YOD1-STAT3信号轴.
- 准YOD1-STAT3通路为心脏缩提供了一个有前途的治疗策略.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
65
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
65
Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59
Cardiomyopathy IV: Restrictive Cardiomyopathy
44
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
44
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K


